Elemental impurity risk management can help biomanufacturers to maintain regulatory alignment and ensure patient safety.

Biopharmaceutical company Rakuten announced the signing of a manufacturing partnership with contract development and ...

Last week, biotechnology company Ascidian Therapeutics announced a manufacturing partnership with gene-therapy–focused ...

North Carolina Governor Josh Stein announced that pharmaceutical giant Johnson & Johnson (J&J) will expand its presence in ...

Validated next-generation sequencing soon will become necessary in ensuring the safety and efficacy of cell and gene ...

Meanwhile, Novotech has appointed Anand Tharmaratnam as its own new CEO. Tharmaratnam has over 30 years of industry ...

The Priority Review Voucher (PRV) program is designed to incentivize rare disease drug development.

Ludwig Macko is head of development for Genedata's Selector software platform for NGS data analysis.

Stéphane Bancel, CEO of vaccine maker Moderna, addressed shareholders in a letter that dissected the events of 2025 while ...

But cell and gene therapies (CGTs) are catching up. During Cell and Gene Therapy International Europe 2025, held in Berlin, ...

Contract development and manufacturing organization (CDMO) Rentschler Biopharma has announced a partnership with ...

Contract development and manufacturing organization (CDMO) Samsung Biologics made a splash at the end of 2025, acquiring ...